Clinical Trials Logo
  1. Home
  2. Circulating Tumor DNA
  3. NCT05027828

CtDNA as a Novel Biomarker of Treatment Efficacy in Patients With Ovarian Cancer

Circulating Tumor DNA Clinical Trial

Official title:
Circulating Tumor DNA as a Novel Molecular Marker of Treatment Efficacy to Guide Targeted Maintenance Therapy for Patients With High Grade Serous Ovarian Cancer

Clinical Trial Summary

This study is a prospective observational clinical trial. Patients who were diagnosed and treated for the first time were enrolled and their surgical pathology was confirmed to be high-grade serous ovarian cancer. At the same time, these patients will receive first-line maintenance treatment with PARP inhibitors after traditional chemotherapy. During the trial period, patients' plasma will be collected before surgery, after chemotherapy, during targeted maintenance therapy, and during disease progression, and ctDNA-specific genomes will be detected, and clinical data will be collected over the same period. It is expected that specific ctDNA can be used to predict the efficacy of PARP inhibitors in patients with ovarian cancer, and to detect the recurrence of the disease early.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT05027828
Study type Observational
Source Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
Contact
Status Recruiting
Phase
Start date May 1, 2024
Completion date September 30, 2024
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT05167604 - Clinical Value of MRD Monitoring for Adjuvant Therapy in Postoperative NSCLC
Recruiting NCT05598528 - Exploring the Mechanism of Primary Resistance to Third-generation EGFR-TKIs as First-line Treatment in EGFR-positive Advanced NSCLC (PRECISE Study)
Recruiting NCT04555369 - The Value of ctDNA on Chemotherapy Efficacy for mCRC N/A
Not yet recruiting NCT03688035 - Potential of Circulating Tumor DNA to Assess the Tumor Response to Neoadjuvant Chemotherapy in Breast Cancer Patients
Recruiting NCT03737539 - Dynamic Monitoring of ctDNA Methylation to Predict Relapse in Colorectal Cancer After Radical Resection (POSTCA)
Not yet recruiting NCT04511559 - Methylation Analysis of Circulating Tumor DNA in Gastric Cancer
Recruiting NCT03748680 - IMPROVE Intervention Trial Implementing Non-invasive Circulating Tumor DNA Analysis to Optimize the Operative and Postoperative Treatment for Patients With Colorectal Cancer Phase 2
Completed NCT02620527 - Concordance Between ctDNA Assay and FoundationOne
Recruiting NCT05601505 - Circulating Tumor DNA-guided Neoadjuvant Treatment Strategy for Locally Advanced Rectal Cancer Phase 2
Recruiting NCT05529615 - Circulating Tumor DNA Guided Adjuvant Chemotherapy for Colon Cancer N/A
Recruiting NCT05161585 - Evaluation of Circulating Tumor DNA Guided Surveillance Strategy of Stage III Colorectal Cancer: an Open, Prospective, Randomized Controlled Cohort Study N/A
Recruiting NCT05390112 - Cohort Study of Patients With Hepatocellular Carcinoma and Circulating Tumor DNA Monitoring of Chemoembolization
Recruiting NCT06434896 - Circulating Tumor DNA Based Adjuvant Chemotherapy in Stage II Colon Cancer Patients: the MEDOCC-CrEATE Trial N/A
Recruiting NCT04966663 - Using ctDNA to Determine Therapies for Lung Cancer Phase 2
Recruiting NCT05801263 - ctDNA Methylation for Epithelial Ovarian Cancer
Recruiting NCT05801276 - ctDNA Methylation for Detecting Ovarian Cancer
Active, not recruiting NCT04276337 - Genetic Characteristics of HER2 Positive Breast Cancer With Neoadjuvant TCHP Chemotherapy
Recruiting NCT05969938 - Predicting the Efficacy and Prognosis of Rectal Cancer Patients Based on ctDNA-MRD Technology
Completed NCT04456972 - Reliability and Interest of Circulating Tumor DNA in Endometrial Cancers. N/A
Completed NCT06404593 - Dynamic ctDNA Detection for Colorectal Cancer Liver Metastases